Archive - NewLimit Blog

NewLimit raises $130 million Series B led by Kleiner Perkins alongside NFDG, Khosla Ventures, Human Capital and others

NewLimit is developing medicines to extend human healthspan through epigenetic reprogramming

58 mins ago •

Brian Armstrong

,

,

, and

Jacob C. Kimmel

March 2025

2025 NewLimit Progress Update

Mar 22 •

Jacob C. Kimmel

January // February 2025 Progress Update

Therapeutic beginnings

Mar 14 •

Jacob C. Kimmel

January 2025

2024 Year in Review

Restoring youthful function

Jan 9 •

Jacob C. Kimmel

November 2024

September // October 2024 Progress Update

In chimerico reprogramming

Nov 11, 2024 •

Jacob C. Kimmel

September 2024

July // August 2024 Progress Update

Completing the discovery cycle

Sep 16, 2024 •

Jacob C. Kimmel

July 2024

May // June 2024 Update

Reversing phenotypic age

Jul 5, 2024 •

Jacob C. Kimmel

June 2024

Markus Grompe is joining our Scientific Advisory Board

We’re excited to announce that Markus Grompe is joining our Scientific Advisory Board to support our Metabolism program.

Jun 11, 2024 •

Jacob C. Kimmel

May 2024

2024 May Progress Update - Live Event!

The days are long, the years are short

May 10, 2024 •

Jacob C. Kimmel

March 2024

January 2024

2023 Year in Review

Construction ends. The search begins.

Jan 9, 2024 •

Jacob C. Kimmel

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts